Update: What evidence is available on the off-label use of dexmedetomidine for alcohol withdrawal syndrome?
txt 1
Dexmedetomidine is an alpha2-adrenergic agonist commonly used for sedation in both mechanically ventilated patients and for procedural sedation in non-intubated patients.¹ Interest in its use as an adjunctive therapy for alcohol withdrawal began over a decade ago; however, its place in therapy for this indication remains uncertain.2 The University of Illinois Drug Information Group first addressed this topic in a 2013 frequently asked question (FAQ), which identified only 1 prospective study involving 18 patients.3 A 2016 update to the FAQ (available here) incorporated additional evidence, including 2 randomized controlled trials (RCTs).4-6 By 2020, dexmedetomidine had been incorporated into clinical practice guidelines from the American Society of Addiction Medicine (ASAM), prompting another FAQ (available here) update to reflect both the evolving literature and guideline recommendations.7,8 Despite this, only 2 additional studies were identified at that time, both retrospective cohort studies.9,10 More recent evidence now warrants a further update to this FAQ.
Guideline recommendations for dexmedetomidine in alcohol withdrawal
Briefly, the 2020 ASAM guidelines recommend benzodiazepines as the first-line therapy for patients with moderate alcohol withdrawal.7 Phenobarbital is considered an alternative option but is less preferred compared with benzodiazepines. The guidelines also recommend alpha2-adrenergic agonists (e.g., clonidine, dexmedetomidine) as adjunctive agents for autonomic hyperactivity and anxiety when these symptoms are not adequately controlled with benzodiazepines alone; however, they should not be used to prevent or treat withdrawal-related seizures or delirium, as they are ineffective for these indications.
In 2023, the American Academy of Emergency Medicine (AAEM) published guidelines for emergency department management of patients with alcohol intoxication, alcohol withdrawal, and alcohol use disorder.11 Consistent with ASAM recommendations, benzodiazepines are first-line treatment for moderate alcohol withdrawal. For severe alcohol withdrawal, AAEM recommends either parenteral benzodiazepines or barbiturates. Dexmedetomidine is included as a potential adjunct for patients with severe withdrawal when benzodiazepines alone fail to adequately control symptoms.
Literature review
Additional evidence published after the 2020 FAQ includes 1 randomized trial, observational studies, and meta-analyses of randomized and observational studies.12-18 Two meta-analyses, one published in 2023 by Polintan et al and the other in 2024 by Fiore et al identified 12 and 9 studies, respectively.13,14 The only RCTs included in these meta-analyses are those summarized in the 2016 FAQ by Mueller et al (2014) and Bielka et al (2015).5,6 Overall, the meta-analyses found low-quality evidence consisting primarily of retrospective cohort studies.13,14 A synthesis of pooled data in these meta-analyses failed to demonstrate clear improvement in clinically meaningful outcomes, including intensive care unit (ICU) or hospital length of stay, need for tracheal intubation, or benzodiazepine requirements. In fact, both hospital length of stay and ICU length of stay were improved with standard benzodiazepine therapy rather than dexmedetomidine with mean differences of 53.18 and 48.05 hours, respectively.14 Dexmedetomidine was also consistently associated with increased bradycardia and inconsistently associated with hypotension. The authors expressed concern that while dexmedetomidine may reduce autonomic hyperactivity and provide sedation without respiratory depression, dexmedetomidine does not address the underlying alcohol withdrawal pathophysiology of gamma-aminobutyric acid (GABA) insensitivity and N-methyl-D-aspartate (NMDA) hyperactivation and may mask symptoms of alcohol withdrawal.13,14
Table 1 summarizes the single RCT identified subsequent to the 2020 FAQ, and Table 2 summarizes the observational studies.12,15-18 The RCT has a number of limitations including the small sample size, an entirely male population, the focus on hemodynamic effects, and short duration (10 days). The retrospective cohort studies also have many limitations, and several authors expressed concern over failing to fully control for differences between groups at baseline.
table 1
| Table 1. Summary of recent RCT evaluating dexmedetomidine for alcohol withdrawal syndrome.12 | ||||
|---|---|---|---|---|
| Study | Subjects | Interventions | Results | Conclusions |
| García-Méndez et al 2021 | 40 patients with AWS from a single center in Mexico | Diazepam 5 to 20 mg IV (n=20) Dexmedetomidine 0.2 to 0.7 mcg/kg/min limited to 72-hour duration (n=20) | First 24-hour median HR was significantly lower with dexmedetomidine (73.85 vs 67.10; p=0.002). No significant difference in median HR when measured over the entire treatment time (111.50 vs 118.35; p=0.067). SBP was lower with dexmedetomidine (143.85 vs 137.95; p=0.001) CIWA-Ar scores were lower at 12 hours with dexmedetomidine (7.6 vs 10; p=0.001) but similar at 24 hours (2 vs 2.5; p=0.051). For most patients, treatment duration was longer with diazepam. | Dexmedetomidine improved HR, SBP, and resulted in fewer treatment days compared to standard diazepam treatment. |
| Abbreviations: AWS=alcohol withdrawal syndrome; CIWA=Clinical Institute Withdrawal Assessment for Alcohol – Revised; HR=heart rate; IV=intravenous; RCT=randomized controlled trial; SBP=systolic blood pressure. | ||||
table 2
| Table 2. Summary of recent observational studies evaluating dexmedetomidine for alcohol withdrawal syndrome.15-18 | ||||
|---|---|---|---|---|
| Study | Subjects | Interventions | Results | Conclusions |
| Ashok et al 202515 Retrospective Cohort | 975 patients with AWS from a single center in the US admitted to ICU or a progressive care unit | SOC consisting of benzodiazepines with or without barbiturates (n=371) Dexmedetomidine (usual dose 0.2 to 0.7 mcg/kg/min) + SOC (n=623) | Median LOS longer with dexmedetomidine (10 days vs 5 days; p<0.0001) Median ICU LOS longer with dexmedetomidine (4.9 days vs 1.9 days; p<0.0001) Lorazepam doses and 30-day readmission rates were not significantly different between groups. | Although dexmedetomidine was associated with longer hospital and ICU stays without reducing benzodiazepine needs, this may be due to differences in illness severity. |
| Matecki et al 202516 Retrospective Cohort | 156 patients with AWS hospitalized at a single center in the US | Phenobarbital with a maximum dose of 20 mg/kg (n=54) Dexmedetomidine (dosing not provided) (n=102) All patients received lorazepam. | Mean LOS longer with dexmedetomidine (9 days vs 6 days; p=0.05) Median ICU LOS similar between groups with mean of 4 days (p=0.241) In the GLM analysis, the phenobarbital group had lower probability of intubation (OR, 0.33; 95% CI, 0.15-0.70; p=0.005), shorter hospital LOS (IRR, 0.45: 95% CI, 0.31-0.64; p < 0.001) and shorter ICU LOS (IRR 0.58; 95% CI, 0.34-1.00; p=0.050). | Adjunct phenobarbital lowers hospital LOS compared to adjunct dexmedetomidine. |
| Ware et al 202317 Retrospective cohort | 112 patients with AWS hospitalized at a single center in the US | Dexmedetomidine (median rate of 0.7 mcg/kg/hour) (n=56) No dexmedetomidine (n=56) All patients received phenobarbital. | Multivariate linear regression analysis showed dexmedetomidine was independently associated with increased ICU LOS by 49.8 hours (p=0.008). Hospital LOS was longer in the dexmedetomidine group (233.5 hours vs 180.5 hours; p=0.017). | Adjunctive dexmedetomidine is associated with prolonged ICU LOS; however, it is possible that this is due to a sicker patient population that was not accounted for in adjustment for baseline characteristics. |
| Collier et al 202218 Retrospective cohort | 147 patients with AWS admitted to the ICU at a single center in the US | Dexmedetomidine (dosing not provided) (n=56) No dexmedetomidine (n=91; 55 after PS matching) All patients received benzodiazepines, and adjunctive agents such as propofol, valproic acid, gabapentin, clonidine, baclofen, alcohol, and antipsychotics were permitted in both groups. | Median change in CIWA-Ar favored the dexmedetomidine group initially (3.9 vs 1.5; p=0.117) but then the control group after PS matching (5.4 vs 3.8; p=0.223); however, there was no significant difference in either analysis. Median ICU benzodiazepine requirements were higher in the dexmedetomidine group (24 mg vs 20.5 mg; p=0.001). Median ICU LOS was significantly longer in the dexmedetomidine group (6 days vs 3 days; p=0.05), but hospital LOS was similar (9 days vs 7 days; p=0.842). Bradycardia was more common with dexmedetomidine (25.5% vs 12.7%; p=0.215), but the difference was not statistically significant. | The addition of dexmedetomidine to benzodiazepines did not improve CIWA-Ar scores to a greater extent than standard treatment. |
| Abbreviations: AWS=alcohol withdrawal syndrome; CI=confidence interval; CIWA-Ar=Clinical Institute Withdrawal Assessment for Alcohol – Revised; GLM=generalized linear models; ICU=intensive care unit; IRR=incidence rate ratio; LOS=length of stay; OR=odds ratio; PS=propensity score; SOC=standard of care. | ||||
txt 3
Discussion
Although the evidence has accumulated with each FAQ update, the role of dexmedetomidine as an adjunctive therapy for patients with alcohol withdrawal syndrome remains unclear. Although guidelines recommend its use for patients who have severe withdrawal symptoms uncontrolled with benzodiazepines, recent evidence raises concerns about dexmedetomidine safety and efficacy in this population. No well-designed controlled trials have been published, and most of the recently published literature supports the use of benzodiazepines as the primary therapy with increasing support of phenobarbital in patients with more severe symptoms.
References
- Precedex [package insert]. Lake Forest, IL: Hospira, Inc.; 2026.
- Riggan M, Schmitz Z, Hoffman RS, Biary N, Biary R. Dexmedetomidine for Alcohol Withdrawal: Looks Can Be Deceiving. Cureus. 2025;17(10):e95851. doi:10.7759/cureus.95851
- Tolonen J, Rossinen J, Alho H, Harjola VP. Dexmedetomidine in addition to benzodiazepine-based sedation in patients with alcohol withdrawal delirium. Eur J Emerg Med. 2013;20(6):425-427. doi: 10.1097/MEJ.0b013e32835c53b3
- Gabay M. Is there updated information on the off-label use of dexmedetomidine (Precedex) for alcohol withdrawal syndrome? University of Illinois at Chicago Drug Information Group. Published December 2016. Accessed June 15, 2026. https://dig.pharmacy.uic.edu/faqs/2016-2/december-2016-faqs/
- Bielka K, Kuchyn I, Glumcher F. Addition of dexmedetomidine to benzodiazepines for patients with alcohol withdrawal syndrome in the intensive care unit: a randomized controlled study. Ann Intensive Care. 2015;5(1):33. doi: 10.1186/s13613-015-0075-7
- Mueller SW, Preslaski CR, Kiser TH, et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med. 2014;42(5):1131-1139. doi:10.1097/CCM.0000000000000141
- Wong J, Saver B, Scanlan JM, et al. The ASAM clinical practice guideline on alcohol withdrawal management. J Addict Med. 2020;14(3S Suppl 1):1-72. doi:10.1097/ADM.0000000000000668
- Hartke P. Update: What evidence is available on the off-label use of dexmedetomidine for alcohol withdrawal syndrome? Published November 2020. Accessed June 15, 2026. https://dig.pharmacy.uic.edu/faqs/2020-2/november-2020-faqs/update-what-evidence-is-available-on-the-off-label-use-of-dexmedetomidine-for-alcohol-withdrawal-syndrome/
- Yavarovich ER, Bintvihok M, McCarty JC, Breeze JL, LaCamera P. Association between dexmedetomidine use for the treatment of alcohol withdrawal syndrome and intensive care unit length of stay. J Intensive Care. 2019;7:49. doi: 10.1186/s40560-019-0405-1
- Love K, Zimmermann AE. Use of propofol plus dexmedetomidine in patients experiencing severe alcohol withdrawal in the intensive care unit. J Clin Pharmacol. 2020;60(4):439-443. doi: 10.1002/jcph.1539
- Strayer RJ, Friedman BW, Haroz R, et al. Emergency Department Management of Patients With Alcohol Intoxication, Alcohol Withdrawal, and Alcohol Use Disorder: A White Paper Prepared for the American Academy of Emergency Medicine. J Emerg Med. 2023;64(4):517-540. doi:10.1016/j.jemermed.2023.01.010
- García-Méndez N, Briceño-Santana M, Totomoch-Serra A, et al. The hemodynamic effects of diazepam versus dexmedetomidine in the treatment of alcohol withdrawal syndrome: A randomized clinical trial. Med Clin (Barc). 2021;157(12):561-568. doi:10.1016/j.medcli.2020.09.023
- Fiore M, Alfieri A, Torretta G, et al. Dexmedetomidine as Adjunctive Therapy for the Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis. Pharmaceuticals (Basel). 2024;17(9):1125. doi:10.3390/ph17091125
- Polintan ETT, Danganan LML, Cruz NS, et al. Adjunctive Dexmedetomidine in Alcohol Withdrawal Syndrome: A Systematic Review and Meta-analysis of Retrospective Cohort Studies and Randomized Controlled Trials. Ann Pharmacother. 2023;57(6):696-705. doi:10.1177/10600280221130458
- Ashok A, Sharma R, Ahmed S, et al. Assessment of the Treatment for Alcohol Withdrawal Syndrome With and Without Dexmedetomidine: A Retrospective Cohort Study. J Clin Med Res. 2025;17(11):601-607. doi:10.14740/jocmr6361
- Matecki M, Noureldin A, Akkari R, et al. Phenobarbital Addition to Alcohol Withdrawal Treatment Offers Better Outcomes than Dexmedetomidine in Hospitalized Patients. J Intensive Care Med. 2025;40(9):948-955. doi:10.1177/08850666251328881
- Ware LR, Schuler BR, Goodberlet MZ, Marino KK, Lupi KE, DeGrado JR. Evaluation of Dexmedetomidine as an Adjunct to Phenobarbital for Alcohol Withdrawal in Critically Ill Patients. J Intensive Care Med. 2023;38(6):553-561.
- Collier TE, Farrell LB, Killian AD, Kataria VK. Effect of Adjunctive Dexmedetomidine in the Treatment of Alcohol Withdrawal Compared to Benzodiazepine Symptom-Triggered Therapy in Critically Ill Patients: The EvADE Study. J Pharm Pract. 2022;35(3):356-362. doi:10.1177/0897190020977755 doi:10.1177/08850666231152837
Prepared by:
Courtney Krueger, PharmD, BCPS
Clinical Assistant Professor, Drug Information Specialist
University of Illinois at Chicago College of Pharmacy
July 2026
The information presented is current as of June 15, 2026. This information is intended as an educational piece and should not be used as the sole source for clinical decision-making.